These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Vaccination of patients with metastatic renal cancer with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside interferon-alpha. Hawkins RE; Macdermott C; Shablak A; Hamer C; Thistlethwaite F; Drury NL; Chikoti P; Shingler W; Naylor S; Harrop R J Immunother; 2009 May; 32(4):424-9. PubMed ID: 19342962 [TBL] [Abstract][Full Text] [Related]
10. Cross-trial analysis of immunologic and clinical data resulting from phase I and II trials of MVA-5T4 (TroVax) in colorectal, renal, and prostate cancer patients. Harrop R; Shingler W; Kelleher M; de Belin J; Treasure P J Immunother; 2010; 33(9):999-1005. PubMed ID: 20948436 [TBL] [Abstract][Full Text] [Related]
11. Immune evasion mechanisms in colorectal cancer liver metastasis patients vaccinated with TroVax (MVA-5T4). Elkord E; Dangoor A; Burt DJ; Southgate TD; Daayana S; Harrop R; Drijfhout JW; Sherlock D; Hawkins RE; Stern PL Cancer Immunol Immunother; 2009 Oct; 58(10):1657-67. PubMed ID: 19221742 [TBL] [Abstract][Full Text] [Related]
12. Vaccination of castration-resistant prostate cancer patients with TroVax (MVA-5T4) in combination with docetaxel: a randomized phase II trial. Harrop R; Chu F; Gabrail N; Srinivas S; Blount D; Ferrari A Cancer Immunol Immunother; 2013 Sep; 62(9):1511-20. PubMed ID: 23877659 [TBL] [Abstract][Full Text] [Related]